Further Weakness as Enanta Pharmaceuticals (NASDAQ:ENTA) Drops 15% This Week, Taking Five-year Losses to 84%

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders should be happy to see the share price up 20% in the last quarter. But will that repair the damage for the weary investors who have owned thi

Simply Wall StApr 18 18:37

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indica

Enanta PharmaceuticalApr 17 12:00

Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint

Seeking AlphaMar 19 05:45

Madrigal Climbs Amid Hopes for New NASH Drug; B. Riley Upgrades

Seeking AlphaMar 15 20:19

Madrigal and Liver Drug Developers Fall Ahead of FDA Decision on NASH Therapy

Seeking AlphaMar 14 22:42

Liver Drug Developers Outperform as U.S. Awaits First NASH Drug

Seeking AlphaMar 14 01:29